Pharma-Bio Serv (PBSV) Equity Average (2011 - 2026)

Pharma-Bio Serv (PBSV) has 14 years of Equity Average data on file, last reported at $11.1 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 13.84% year-over-year to $11.1 million; the trailing twelve-month figure through Jan 2026 stood at $11.1 million (down 13.84% YoY), and the FY2025 full-year result was $12.8 million, down 14.12% from the prior year.
• Equity Average for Q1 2026 stood at $11.1 million, down from $11.9 million in the prior quarter.
• Across five years, Equity Average topped out at $18.2 million in Q1 2022 and bottomed at $11.1 million in Q1 2026.
• The 5-year median for Equity Average is $15.1 million (2024), against an average of $14.7 million.
• The widest annual swing landed in 2022, when Equity Average declined 29.4%; it then declined 0.57% in 2023.
• A 5-year view of Equity Average shows it stood at $16.4 million in 2022, then slipped by 1.2% to $16.2 million in 2023, then decreased by 15.2% to $13.7 million in 2024, then retreated by 13.0% to $11.9 million in 2025, then decreased by 7.08% to $11.1 million in 2026.
• The last three Equity Average figures came in at $11.1 million (Q1 2026), $11.9 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.

Peer Comparison